Recent developments in immunosuppressive therapy have focused on reducing toxicity while maintaining efficacy. This includes the development of biologics and targeted therapies that offer more specific immune modulation. Advances in pharmacogenomics are also helping to tailor immunosuppressive therapy to individual patients, potentially reducing adverse effects by considering genetic factors that influence drug metabolism.
